JP Morgan Jumps Onto Marijuana Stock Bandwagon with GW Pharmaceuticals

Cannabis Now
By Chris RobertsJan 8, 2019, 7:00 pm394 pts
The time to buy stock in GW Pharmaceuticals, the UK-based company that produces FDA-approved cannabinoid-based medicines to treat epilepsy and other diseases, was in late 2014, when shares in the company were trading at around $80. Or maybe it was late 2016, when share prices were closer to $40. Or better yet,…

Read Article Share
Share Article
- email
- twitter
- facebook
- pocket
- reddit
- tumblr
- linkedin
- pinterest

Trending Today on NewsBudz

The Congressional Cannabis Caucus Still Hasn’t Held A Meeting Six Months Into This Session, Co-Chair Says 63

Cannabis IP Licensing 101 62

Newly-Imposed Tax Hikes on Retail Cannabis Products Take Effect in Two States 61

TerrAscend Exiting Michigan, Will Sell 4 Cultivation Facilities, 20 Dispensaries 58

Weed company hires controversial politician in bid to change federal pot policy 57

Delaware to Commence Adult-Use Cannabis Sales on Aug. 1—831 Days Since Legalization 57

Cannabis Jobs Update – July 2025 56

Are THC potency caps a move toward marijuana prohibition? Debate is brewing 54

About NewsBudz

NewsBudz is your go-to app for daily cannabis news, covering everything from medical marijuana breakthroughs to recreational cannabis trends and legalization updates.

Our platform aggregates content from over 30 top-tier cannabis news outlets to deliver a curated stream of the latest headlines, insights, and developments across the marijuana and hemp industries.

Whether you're interested in policy reform, health research, cannabis business, CBD, delta 9 products or lifestyle stories, NewsBudz keeps you informed and connected. Accessible on the web and mobile, NewsBudz makes it easy to explore, read, and share cannabis news anytime, anywhere.